Synonym
Namoxyrate; W 1760A; W-1760A; W1760A; W 1769A; W-1769A; W1769A.
IUPAC/Chemical Name
(1,1'-Biphenyl)-4-acetic acid, alpha-ethyl-, compd. with 2-(dimethylamino)ethanol (1:1)
InChi Key
SNUBSRMFCPAKSI-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H16O2.C4H11NO/c1-2-15(16(17)18)14-10-8-13(9-11-14)12-6-4-3-5-7-12;1-5(2)3-4-6/h3-11,15H,2H2,1H3,(H,17,18);6H,3-4H2,1-2H3
SMILES Code
O=C(O)C(CC)C1=CC=C(C2=CC=CC=C2)C=C1.CN(CCO)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
329.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Costa A, Nájera C, Sansano JM. Synthetic applications of o- and p-halobenzyl sulfones as zwitterionic synthons: preparation of ortho-substituted cinnamates and biarylacetic acids. J Org Chem. 2002 Jul 26;67(15):5216-25. PubMed PMID: 12126409.
2: Emele JF, Shanaman JE. Analgesic acitivity of namoxyrate (2-[4-biphenylyl] butyric acid 2-dimethylaminoethanol salt). Arch Int Pharmacodyn Ther. 1967 Nov;170(1):99-107. PubMed PMID: 6056595.
3: Dicarlo FJ, Coutinho CB, Haynes LJ, Sklow NJ. Metabolism of namoxyrate by the rat. Arch Int Pharmacodyn Ther. 1967 May;167(1):206-16. PubMed PMID: 6035098.
4: Cohen A, Corgill DA, Abruzzi W, Ligon CW, DeFelice EA. Double-blind comparison of namoxyrate and d-propoxyphene: a cooperative clinical trial. J New Drugs. 1966 Jan-Feb;6(1):38-44. PubMed PMID: 5330694.
5: Cohen A, DeFelice EA, Beber CR, Shaffer JW, Forbes JA. Evaluation of namoxyrate in the treatment of geriatric arthritics. Curr Ther Res Clin Exp. 1965 Dec;7(12):759-68. PubMed PMID: 4954446.
6: Denko CW, DeFelice EA, Shaffer J. Namoxyrate in rheumatic disorders. Curr Ther Res Clin Exp. 1965 Dec;7(12):749-58. PubMed PMID: 4954445.
7: Bergen JR, Resnick O, DeFelice EA, Freeman H. Characteristics of the circulatory transport of C-14-labeled namoxyrate. Curr Ther Res Clin Exp. 1965 Dec;7(12):741-8. PubMed PMID: 4954444.
8: Rider JA, DeFelice EA, Puletti EJ, Moeller HC. Double-blind comparison of effects of aspirin and namoxyrate on pH of gastric secretions, fecal blood loss, serum iron, and iron-binding capacity in normal volunteers. Curr Ther Res Clin Exp. 1965 Oct;7(10):633-8. PubMed PMID: 4954889.
9: RESNICK O, DEFELICE EA, BERGEN JR, FREEMAN H. THE METABOLISM OF NAMOXYRATE CONTAINING ISOTOPIC CARBON IN MAN. Curr Ther Res Clin Exp. 1965 Aug;7:443-50. PubMed PMID: 14331672.
10: CORGILL DA, LIGON CW, DEFELICE EA. DOUBLE-BLIND COMPARISON OF NAMOXYRATE, CODEINE, ASPIRIN, AND PLACEBO. Curr Ther Res Clin Exp. 1965 May;7:263-74. PubMed PMID: 14286205.
11: Cohen A, DeFelice EA. Double-blind evaluation of namoxyrate, codeine, aspirin, and placebo. J New Drugs. 1965 May-Jun;5(3):53-61. PubMed PMID: 5318983.
